Clinical Significance of Preoperative Pyrazinamide-Containing Therapy in Tuberculous Constrictive Pericarditis

References

• Welch TD, Oh JK. Constrictive pericarditis. Cardiol Clin. 2017;35(4):539–549. doi:10.1016/j.ccl.2017.07.007
   PubMed Web of Science ®Google Scholar
• George TJ, Arnaoutakis GJ, Beaty CA, et al. Contemporary etiologies, risk factors, and outcomes after pericardiectomy. Ann Thorac Surg. 2012;94(2):445–451. doi:10.1016/j.athoracsur.2012.03.079
   PubMed Web of Science ®Google Scholar
• Noubiap JJ, Agbor VN, Ndoadoumgue AL, et al. Epidemiology of pericardial diseases in Africa: a systematic scoping review. Heart. 2019;105(3):180–188. doi:10.1136/heartjnl-2018-313922
   PubMed Web of Science ®Google Scholar
• Karima T, Nesrine BZ, Hatem L, et al. Constrictive pericarditis: 21 years’ experience and review of literature. Pan Afr Med J. 2021;38:141. doi:10.11604/pamj.2021.38.141.22884
   PubMed Web of Science ®Google Scholar
• Fang LK, Yu GC, Huang JP, et al. Predictors of postoperative complication and prolonged intensive care unit stay after complete pericardiectomy in tuberculous constrictive pericarditis. J Cardioth Surg. 2020;15(1):148–155. doi:10.1186/s13019-020-01198-9
   PubMed Web of Science ®Google Scholar
• Welch TD. Constrictive pericarditis: diagnosis, management and clinical outcomes. Heart. 2018;104(9):725–731. doi:10.1136/heartjnl-2017-311683
   PubMed Web of Science ®Google Scholar
• Inamdar KY, Aikebaier M, Mulati A. Pericardiectomy: prompt surgical management of constrictive pericarditis. Heart Surg Forum. 2014;17(6):E319–22. doi:10.1532/HSF98.2013183
   PubMed Web of Science ®Google Scholar
• Adler Y, Charron P, Imazio M, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European society of cardiology (ESC) Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921–2964. doi:10.1093/eurheartj/ehv318
   PubMed Web of Science ®Google Scholar
• Depboylu BC, Mootoosamy P, Vistarini N, et al. Surgical treatment of constrictive pericarditis. Texas Heart Inst J. 2017;44(2):101–106. doi:10.14503/THIJ-16-5772
   PubMed Web of Science ®Google Scholar
• Dybowska M, Blasinska K, Gatarek J, et al. Tuberculous pericarditis-own experiences and recent recommendations. Diagnostics. 2022;12(3):619. doi:10.3390/diagnostics12030619
   Web of Science ®Google Scholar
• Syed FF, Schaff HV, Oh JK. Constrictive pericarditis--A curable diastolic heart failure. Nat Rev Cardiol. 2014;11(9):530–544. doi:10.1038/nrcardio.2014.100
   PubMed Web of Science ®Google Scholar
• Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation. 2005;112(23):3608–3616. doi:10.1161/CIRCULATIONAHA.105.543066
   PubMed Web of Science ®Google Scholar
• Fang L, Yu G, Ye B, et al. The optimal duration of anti-tuberculous therapy before pericardiectomy in constrictive tuberculous pericarditis. J Cardiothorac Surg. 2021;16(1):313. doi:10.1186/s13019-021-01691-9
   PubMed Web of Science ®Google Scholar
• Zumla A, Raviglione M, Hafner R, et al. Tuberculosis. New Engl J Med. 2013;368(8):745–755. doi:10.1056/NEJMra1200894
   PubMed Web of Science ®Google Scholar
• Cho YH, Schaff HV. Extent of pericardial resection for constrictive pericardiectomy. Ann Thorac Surg. 2012;94(6):2180. doi:10.1016/j.athoracsur.2012.04.116
   PubMed Web of Science ®Google Scholar
• Via LE, Savic R, Weiner DM, et al. Host-mediated bioactivation of pyrazinamide: implications for efficacy, resistance, and therapeutic alternatives. ACS Infect Dis. 2015;1(5):203–214. doi:10.1021/id500028m
   PubMed Web of Science ®Google Scholar
• Yadon AN, Maharaj K, Adamson JH, et al. A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide. Nat Commun. 2017;8(1):588. doi:10.1038/s41467-017-00721-2
   PubMedGoogle Scholar
• Stehr M, Elamin AA, Singh M. Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria. Expert Rev Anti Infect Ther. 2015;13(5):593–603. doi:10.1586/14787210.2015.1021784
   PubMed Web of Science ®Google Scholar
• Wahan SK, Sharma S, Chawla PA. Anti-tubercular activity of pyrazinamide conjugates: synthesis and structure-activity relationship studies. Mini Rev Med Chem. 2023;23(6):700–718. doi:10.2174/1389557522666220819092431
   PubMed Web of Science ®Google Scholar
• Prideaux B, Via LE, Zimmerman MD, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nature Med. 2015;21(10):1223–1227. doi:10.1038/nm.3937
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Davies GR. The Treatment of Tuberculosis. Clin Pharmacol Ther. 2021;110(6):1455–1466. doi:10.1002/cpt.2261
   PubMed Web of Science ®Google Scholar
• Krug S, Gupta M, Kumar P, et al. Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide. Nat Commun. 2023;14(1):8161. doi:10.1038/s41467-023-43937-1
   PubMedGoogle Scholar
• Pasipanodya JG, Mubanga M, Ntsekhe M, et al. Tuberculous pericarditis is multibacillary and bacterial burden drives high mortality. EBioMedicine. 2015;2(11):1634–1639. doi:10.1016/j.ebiom.2015.09.034
   PubMed Web of Science ®Google Scholar
• Liu QX, Tang DY, Xiang X, et al. Associations between nutritional and immune status and clinicopathologic factors in patients with tuberculosis: a comprehensive analysis. Front Cell Infect Microbiol. 2022;12:1013751. doi:10.3389/fcimb.2022.1013751
   PubMed Web of Science ®Google Scholar
• Sinha P, Davis J, Saag L, et al. Undernutrition and tuberculosis: public health implications. J Infect Dis. 2019;219(9):1356–1363. doi:10.1093/infdis/jiy675
   PubMed Web of Science ®Google Scholar
• Subbian S, Tsenova L, Yang G, et al. Chronic pulmonary cavitary tuberculosis in rabbits: a failed host immune response. Open Biol. 2011;1(4):110016. doi:10.1098/rsob.110016
   PubMedGoogle Scholar
• Blanc L, Sarathy JP, Alvarez Cabrera N, et al. Impact of immunopathology on the antituberculous activity of pyrazinamide. J Exp Med. 2018;215(8):1975–1986. doi:10.1084/jem.20180518
   PubMed Web of Science ®Google Scholar
• Gopal P, Gruber G, Dartois V, et al. Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide. Trends Pharmacol Sci. 2019;40(12):930–940. doi:10.1016/j.tips.2019.10.005
   PubMed Web of Science ®Google Scholar
• Pranger AD, van der Werf TS, Kosterink JGW, et al. The role of fluoroquinolones in the treatment of tuberculosis in 2019. Drugs. 2019;79(2):161–171. doi:10.1007/s40265-018-1043-y
   PubMed Web of Science ®Google Scholar